{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:09:32Z","timestamp":1722884972618},"reference-count":19,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T00:00:00Z","timestamp":1343001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background:<\/jats:p><jats:p>Although high\u2010dose statin therapy has been reported to improve outcomes in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), patterns of statin usage for such patients have not been reported in real\u2010world clinical practice.<\/jats:p><jats:p>Hypothesis:<\/jats:p><jats:p>Some clinical factors would affect the pattern of statin usage in patients with ACS.<\/jats:p><jats:p>Methods:<\/jats:p><jats:p>In the multicenter prospective registry, 3362 patients with ACS who underwent PCI were analyzed. High\u2010dose statin treatment was defined as atorvastatin \u226540 mg or rosuvastatin \u226520 mg per day. The patterns of statin usage were investigated for 30 days after the index PCI.<\/jats:p><jats:p>Results:<\/jats:p><jats:p>High\u2010dose statins were administered prior to PCI to 13.7% and 19.6% of patients with unstable angina\/non\u2013ST\u2010elevated myocardial infarction (UA\/NSTEMI) and ST\u2010elevated myocardial infarction (STEMI), respectively (<jats:italic>P &lt;<\/jats:italic> 0.001). After PCI, 476 (14.2%) patients were maintained on high\u2010dose statins, and 550 (16.4%) patients received no statins. Independent factors associated with high\u2010dose statin usage after PCI were STEMI (odds ratio [OR]: 1.704, 95% confidence interval [CI]: 1.321\u20132.197, <jats:italic>P &lt;<\/jats:italic> 0.001), high total cholesterol level (OR: 1.445, 95% CI: 1.136\u20131.837, <jats:italic>P<\/jats:italic> = 0.003), and current smoker (OR: 1.556, 95% CI: 1.206\u20132.008, <jats:italic>P &lt;<\/jats:italic> 0.011). The absence of hypercholesterolemia was an independent factor determining the nonuse of statins (OR: 0.229, 95% CI: 0.148\u20130.353, <jats:italic>P &lt;<\/jats:italic> 0.001).<\/jats:p><jats:p>Conclusions:<\/jats:p><jats:p>In real\u2010world clinical practice, high\u2010dose statin treatment is being underused despite extensive evidence for patients with ACS undergoing PCI, particularly in UA\/NSTEMI. Efforts are needed to ensure that clinical practice complies with evidence\u2010based guidelines. <jats:italic>Clin. Cardiol.<\/jats:italic> 2012 doi: 10.1002\/clc.22038<\/jats:p><jats:p>This work was supported financially by Pfizer Pharmaceuticals Korea Ltd., which had no role in the study design, data collection, analysis, manuscript writing, or decision to proceed with publication. The authors have no other funding, financial relationships, or conflicts of interest to disclose.<\/jats:p>","DOI":"10.1002\/clc.22038","type":"journal-article","created":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T13:03:10Z","timestamp":1343048590000},"page":"700-706","source":"Crossref","is-referenced-by-count":7,"title":["Current Statin Usage for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Multicenter Survey in Korea"],"prefix":"10.1002","volume":"35","author":[{"given":"Mi\u2010Jeong","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doo Soo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon\u2010Cheol","family":"Gwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo\u2010Joong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyuk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo\u2010Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung\u2010Jea","family":"Tahk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for Korean MUSTANG Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.03.077"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2009.11.021"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.025"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.002451"},{"key":"e_1_2_6_6_2","first-page":"2574","article-title":"ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: executive summary.","volume":"124","author":"Members WC","year":"2011","journal-title":"Circulation."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm355"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.181940"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.188208"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)00397-9"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1711"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2011.41.8.458"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.02.011"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.218685"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa035205"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0907130"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-012-2519-y"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.03.009"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.01.352"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22038","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:53:24Z","timestamp":1697003604000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,23]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1002\/clc.22038"],"URL":"https:\/\/doi.org\/10.1002\/clc.22038","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"type":"print","value":"0160-9289"},{"type":"electronic","value":"1932-8737"}],"subject":[],"published":{"date-parts":[[2012,7,23]]}}}